In particular, BL-8040, a CXCR4 inhibitor, in combination with anti-PD-1 monoclonal antibody or chemotherapy has been shown to efficiently decrease MDSCs and increase CD8+ effector T cells in tumor tissues in patients with pancreatic cancer, resulting in better clinical outcomes [214]. Here, CD8A is linked to neoplasm.